ECMO – Medxy AI

Survival in Cancer Patients with ARDS: The YELENNA Study Challenges ECMO Utility in Severe Cases

By MedXY 12/27/2025

The YELENNA prospective study reveals a 73.2% 90-day mortality rate for cancer patients with ARDS. Crucially, venovenous ECMO provided no survival benefit in severe cases, prompting a re-evaluation of current clinical guidelines and goals-of-care discussions for this high-risk population.

Critical Care news Respiratory

Five-Year Survival and Quality of Life After ECMO: Good Long-Term Outcomes but Persistent Functional Burden

By MedXY 12/11/2025

A large prospective Dutch cohort reports 36% five-year survival after ECMO with generally satisfactory health-related quality of life (median EQ-5D 0.82) but ongoing problems with pain, mobility, activities, and work capacity.

Critical Care Neurology news

Neurologic Complications on VA‑ECMO Are Linked to Higher 6‑Month Mortality: Insights from a Binational Prospective Cohort

By MedXY 12/09/2025

A prospective multicenter cohort of 704 adults on venoarterial ECMO found neurologic complications in 12% and that these events were associated with a 17% absolute increase in death or new disability at 6 months, driven mainly by higher mortality.

Cardiology Critical Care news

Lower-Intensity Anticoagulation During Venovenous ECMO: A Pilot RCT Shows Feasibility and a Signal Toward Less Bleeding

By MedXY 11/05/2025

A 3-center randomized pilot trial found that randomized allocation to low- versus moderate-intensity anticoagulation during venovenous ECMO is feasible, with lower major bleeding rates in the low-intensity arm and no clear excess of thromboembolic events—but the study was underpowered for definitive safety or efficacy conclusions.